BUZZ-Leerink Partners lifts Vertex price target on pipeline optimism
I'm PortAI, I can summarize articles.
Leerink Partners raises Vertex Pharmaceuticals' price target to $525, citing optimism about revenue and pipeline prospects. The brokerage expects encouraging updates from Vertex's kidney pipeline in 2026 and better trial results for IgA nephropathy. Vertex is also negotiating with a third major pharmacy benefit manager for its pain drug. The stock is up 14% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments